Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
- Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (“MDD”) -
- Company speakers include
The Company will provide a program update on CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of MDD, including 4-month durability results from the Company’s Phase 2 trial.
Conference Call and Webcast Details:
Date:
Time:
Dial-in: 800-267-6316 (
Conference ID: CYBN0313
Webcast: Register for the webcast here
The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
About
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311987587/en/
Investor & Media:
Chief Legal Officer
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
Source: